Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Rhea-AI Summary
Ernexa Therapeutics (Nasdaq: ERNA) reported preclinical results for ERNA-101 on May 6, 2026 showing that, in syngeneic ovarian cancer models, ERNA-101 combined with PD-1 blockade achieved complete tumor clearance by bioluminescence and 100% long-term survival.
The data show tumor microenvironment remodeling, increased CD4+/CD8+ infiltration, macrophage reprogramming, reduced ascites, and enhanced T cell persistence. Ernexa plans to advance ERNA-101 toward a first-in-human trial in advanced ovarian cancer and is studying combinations with checkpoint inhibitors.
AI-generated analysis. Not financial advice.
Positive
- Complete tumor clearance and 100% survival in mouse ovarian cancer models with combination therapy
- TME remodeling: shift from immunosuppressive to immune-activated microenvironment
- Increased CD4+/CD8+ tumor infiltration and sustained T cell activity
- Advancing toward first-in-human trial planning for advanced ovarian cancer
Negative
- Findings are from preclinical mouse models; no human clinical efficacy demonstrated yet
- Observed benefit required combination with anti-PD-1, indicating dependency on checkpoint blockade
- Translational risk remains for safety, dosing, and efficacy in humans
News Market Reaction – ERNA
On the day this news was published, ERNA gained 51.38%, reflecting a significant positive market reaction. Argus tracked a peak move of +66.5% during that session. Our momentum scanner triggered 43 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $9.90M at that time. Trading volume was exceptionally heavy at 1493.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner flagged ERNA’s move as stock-specific. While ERNA’s scanned direction was down, peers in the Biotechnology group showed mixed moves: names like MBIO and KZIA were up (3.78%, 3.3%), while BOLT declined 6.99%. No coherent sector-wide trend appears in the data.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Reverse stock split | Negative | -21.2% | Announced 1-for-25 reverse split to regain compliance with Nasdaq bid rule. |
| Mar 31 | Pipeline and financing | Positive | +5.3% | Highlighted ERNA-101 progress toward 2026 trials plus $10.5M financing and cost cuts. |
| Feb 20 | Investor presentation | Neutral | -17.3% | Announced participation in Virtual Investor Closing Bell corporate overview event. |
| Feb 06 | Dilutive offering | Negative | -44.7% | Priced $10.5M best-efforts public offering of common stock and warrants. |
| Feb 03 | FDA pre-IND update | Positive | -25.8% | Reported successful FDA pre-IND meeting and plans for ERNA-101 first-in-human trial. |
Recent news and financing events often led to sharp moves, with positive clinical/regulatory updates sometimes selling off while financings and reverse splits were consistently weak.
Over the last several months, Ernexa has focused on advancing ERNA-101 toward first-in-human trials, securing capital, and maintaining Nasdaq compliance. February 2026 financing and related S-1/424B5 activity raised about $10.5M but coincided with large share-price drops. A planned reverse split announced on Apr 30, 2026 also saw a negative reaction. Earlier, positive pre-IND and catalyst updates produced mixed trading responses. Today’s strong preclinical ovarian cancer data extends this ERNA-101 development narrative from earlier combination and pre-IND disclosures.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-03-13 allows Ernexa to offer up to $50,000,000 in securities and includes an ATM program for up to $9,248,276 of common stock through Brookline Capital Markets. The shelf had 0 recorded usage events in the provided data, but it represents additional authorized financing capacity that could be tapped as development of ERNA-101 progresses.
Market Pulse Summary
The stock surged +51.4% in the session following this news. A strong positive reaction aligns with the striking preclinical ovarian cancer data, showing complete tumor clearance and 100% survival in combination with PD-1 blockade. Historically, ERNA’s clinically positive headlines have produced mixed trading responses, while financings and reverse splits were met with weakness. The existing $50,000,000 shelf and prior dilutive offerings suggest that future capital raises and overall financing needs remained key considerations for sustainability.
Key Terms
pd-1 blockade medical
tumor microenvironment medical
allogeneic medical
induced pluripotent stem cells medical
il-7/il-15 medical
checkpoint inhibitors medical
syngeneic medical
AI-generated analysis. Not financial advice.
Landmark data positions ERNA-101 as a potential game-changing immunotherapy and a major catalyst for future clinical and shareholder value
CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 blockade, drives complete tumor clearance and
“This data represents a significant step forward,” said Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics. “We are not just seeing strong response, we are seeing complete tumor eradication and durable survival, driven by a powerful immune activation mechanism within the tumor itself. These findings underscore the potential of ERNA-101 to overcome one of the biggest challenges in ovarian cancer – an immunologically ‘cold’ TME – and to unlock the full potential of checkpoint inhibition. Subsequent to a positive clinical proof-of-concept trial in collaboration with the MD Anderson Cancer Center in platinum-resistant ovarian cancer, we anticipate broadening the scope of indications to include other solid tumors, where strong immunosuppression in the tumor microenvironment limits the clinical benefit of anti-PD-1 therapy.”
In the study, treatment with ERNA-101 in combination with anti-PD-1 therapy resulted in complete tumor clearance (i.e., loss of detectable tumor signal by bioluminescence imaging) and
The data further demonstrate that ERNA-101 remodels the TME from immunosuppressive to immune-activated, enabling robust and sustained anti-tumor immune responses.
“What we are seeing goes beyond expectations. Achieving complete tumor elimination and
ERNA-101 is an allogeneic induced mesenchymal stem cell (iMSC) therapy derived from induced pluripotent stem cells (iPSCs) and engineered to home to tumors and secrete a potent IL-7/IL-15 fusion cytokine directly within the TME. This localized cytokine delivery approach is designed to maximize immune activation while minimizing systemic toxicity.
Key findings from the preclinical studies include:
- Complete tumor clearance and survival: Combination therapy eliminated detectable tumors and achieved
100% survival in treated mice through long-term follow-up - Tumor microenvironment remodeling: ERNA-101 converted the tumor environment from immunosuppressive to immune-activated, enabling stronger immune attack on the tumor
- Enhanced immune cell activity: Treatment increased the activity, survival, and persistence of key cancer-fighting T cells
- Immune infiltration: Significantly more CD4⁺ and CD8⁺ T cells were able to enter tumors and engage cancer cells directly
- Macrophage reprogramming: Immune cells within the tumor shifted toward a cancer-fighting state rather than a tumor-supporting state
- Reduced disease burden: Treatment reduced tumor burden and decreased ascites fluid accumulation associated with advanced disease
Ovarian cancer, particularly high-grade serous ovarian carcinoma (HGSOC), remains a significant unmet medical need, with most patients diagnosed at advanced stages and high relapse rates following standard therapies. Existing treatments, including checkpoint inhibitors, have shown limited efficacy due to the highly immunosuppressive TME.
Ernexa plans to incorporate these findings into its development strategy as it advances ERNA-101 toward a first-in-human clinical trial in patients with advanced ovarian cancer. Ongoing studies are evaluating ERNA-101 in combination with checkpoint inhibitors and other immuno-oncology agents.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s synthetic, allogeneic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com
Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com
